Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
Last trade$11.26
Day change-$0.13 (-1.14%)
Day range$11.19 – $12.04
Volume734,581
Market cap$1.74B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.74B
Price / earnings
—
Price / book
1.78×
Price / sales
4.36×
EV / sales
4.55×
EV / EBITDA
27.31×
Profitability
Earnings per share
-$0.42
Return on assets
-4.55%
Return on equity
-6.58%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.3×
Current ratio
2.58×
Quick ratio
2.58×
Cash ratio
1.65×
Cash flow
Price / cash flow
21.39×
Price / free cash flow
24.07×
Free cash flow
$72.18M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CERT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$94.9M
$93.27M
$106.92M
$103.65M
$90.89M
$92.36M
$106M
$100.36M
Cost of revenue
$31.44M
$35.12M
$41.62M
$39.17M
$33.4M
$34.29M
$41.52M
$38.26M
Gross profit
$63.46M
$58.15M
$65.3M
$64.48M
$57.49M
$58.07M
$64.48M
$62.1M
Selling, general and administrative
$38.61M
$36.91M
$42.73M
$37.91M
$36.89M
$30.36M
$32.37M
$34.34M
Research and development
$10.77M
$9.71M
$12.29M
$11.28M
$10.27M
$8.97M
$10.52M
$7.77M
Total operating expenses
$61.14M
$58.35M
$69.6M
$63.64M
$58.05M
$50.4M
$56.86M
$56.1M
Operating income
$2.32M
-$196K
-$4.3M
$836K
-$562K
$7.67M
$7.62M
$6M
Interest expense
-$5.04M
-$4.99M
-$4.94M
-$5.12M
-$5.01M
-$4.8M
-$4.81M
-$5M
Income before taxes
-$1.18M
-$6.39M
-$7.94M
-$2.91M
-$3.83M
$4.37M
$4.54M
$2.18M
Income taxes
$2.4M
-$307K
$820K
$2.99M
$1M
$2.87M
-$201K
-$4.4M
Net income
$5.59M
-$55.27M
-$8.76M
-$5.9M
$1.53M
-$1.97M
$4.74M
$6.58M
Net income attributable to common shareholders
$5.59M
-$55.27M
-$8.76M
-$5.9M
$1.53M
-$1.97M
$4.74M
$6.58M
EBITDA
$18.64M
$13.06M
$14.79M
$19.94M
$14.98M
$20.33M
$26.24M
$24.22M
Basic earnings per share
$0.04
-$0.36
-$0.06
-$0.04
$0.01
-$0.01
$0.03
$0.04
Diluted earnings per share
$0.04
-$0.36
-$0.06
-$0.04
$0.01
-$0.01
$0.03
$0.04
Recent news
Company coverage with links to the original publishers.
The global biosimulation market reached USD 4.09 billion in 2025 and is projected to grow at 16.90% CAGR through 2035, reaching USD 19.49 billion. Growth is driven by AI-driven drug discovery, virtual clinical trials, personalized medicine demand, and computational modeling adoption. However, geopolitical instability in the Middle East has created near-term supply chain disruptions and increased pharmaceutical packaging costs by 15-20%. Key players are pursuing strategic acquisitions and platform launches to expand capabilities.
Recent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.
The global in silico clinical trials market, valued at USD 1.84 billion in 2025, is projected to grow to USD 8.94 billion by 2035 at a 15.2% CAGR. Growth is driven by high failure rates in traditional clinical trials, regulatory acceptance of computational evidence, advances in AI and digital twins, and ethical concerns about animal testing. North America dominates the market while Asia Pacific shows the fastest growth.
Law firm Bragar Eagel & Squire is investigating Certara, Inc. for potential securities law violations following the company's Q1 2026 earnings announcement. Certara reported declining services revenue (down 4% YoY to $57.2M) and bookings (down 14% YoY to $66.6M), citing softer performance from major customers and exiting its regulatory business. The stock fell 19% on the news, dropping from $6.31 to $5.13 per share on May 11, 2026.
Law firm Johnson Fistel is investigating Certara, Inc. (NASDAQ: CERT) on behalf of investors who suffered losses following the company's May 2026 earnings report disclosing declining services revenue and bookings, along with execution challenges. The investigation was further prompted by the announcement of CFO John Gallagher's resignation effective July 14, 2026. Investors who purchased Certara securities and experienced losses are encouraged to contact the firm.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.